Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?

Psychopharmacology

Volumn 129, Issue 3, 1997, Pages 197-205

  Sánchez, Connie ^a   Meier, Eddi ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Aggression; Anxiety; Depression; Rodents; Serotonin reuptake inhibitors

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 HYDROXYTRYPTOPHAN; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; PENBUTOLOL; PENTAZOCINE; RADIOLIGAND; RITANSERIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1C RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA1 OPIATE RECEPTOR; SIGMA2 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; BRAIN; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EXPLORATORY BEHAVIOR; FORCED SWIMMING TEST; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SOCIAL ISOLATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY; ULTRASONIC VOCALIZATION; ULTRASOUND; VOCALIZATION;

1-NAPHTHYLAMINE; AGGRESSION; ANIMALS; ANXIETY; BINDING, COMPETITIVE; CITALOPRAM; DEPRESSION; FLUOXETINE; FLUVOXAMINE; MALE; MICE; MOTOR ACTIVITY; PAROXETINE; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; VOCALIZATION, ANIMAL;

EID: 0031050392     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050181     Document Type: Article

References (44)

1. Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biohehav Rev 19 [3]: 377-395
2. Borsini F. Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94: 147-160
3. Bourin M, Colombel M-C, Malinge M, Bradwejn J (1991) Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatr Neurosci 16 [4]: 199-203
4. Castrogiovanni P, Di-Muro A, Maremanni I (1992) Fluoxetine reduces aggressive behavior in depressive outpatients. New Trends Exp Clin Psychiat 8:57
5. Cervo L, Grignaschi G, Rossi C, Samanin R (1991) Role of central serotonergic neurons in the effect of sertraline in rats in the forced swimming test. Eur J Pharmacol 196:217-222
6. Cesana R, Ceci A, Ciprandi C, Borsini F (1993) Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 45:473-475
7. Cornelius JR, Soloff PH, Perel JM, Ulrich RF (1990) Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 26:151-154
8. Dehonnel G, de Montigny C (1996) Modulation of NMDA and dopaminergie neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58:721-734
9. Devane CL (1995) Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 10 [suppl 3]:185-193
10. De Vry J, Benz U, Schreiber R, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249:331-339
11. Doogan DP, Caillard V (1988) Sertraline: a new antidepressant. J Clin Psychiatry 49[8]:46-51
12. Durcan MJ, Lister RG, Eckardt MJ, Linnoila M (1988) Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. Psychopharmacology 96:528-533
13. Fava M, Rosenbaum JF, Pava JA, McCarthy KK, Steingard RJ, Bouffides E (1993) Anger attacks in unipolar depression. Part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 150: 1158-1163
14. 1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci 14:441-448
15. Górka Z, Wojtasik E, Kwiatek H, Maj J (1979) Action of serotoninmimetics in the behavioral despair test in rats. Commun Psychopliarmacol 3:133-136
16. Heym J, Koe BK (1988) Pharmacology of sertraline: a review. J Clin Psychiatry 49[8]: 40-45
17. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9[I]: 19-26
18. Kallioniemi H, Suvälahti E (1993) Citalopram, a specific inhibitor of serotonin re-uptake in treatment of psychotic and borderline patients, Nord J Psychiatr 47 [suppl. 28]: 79-84
19. 1 sites. Eur J Pharmacol 299:21-28
20. Kelly JP, Leonard BE (1994) The effect of tianeptine and sertraline in three animal models of depression. Neuropharmacology 33[8]: 1011-1016
21. Lane R, Baldwin D, Preskorn S (1995) The SSRIs - advantages, disadvantages and differences. J Psychopharmacol 9 [2 suppl S]: 163-178
22. Lightowler S, Kennett GA, Williamson IJR, Blackburn TP, Tulloch IF (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49[2]:281-285
23. Maj J, Rogóz Z, Skuza G (1982) Fluvoxamine. a new antidepressant drug, fails to show antiserotonin activity. Eur J Pharmacol 81:287-292
24. Mogilnicka E, Szyrak A, Maj J (1987) Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur J Pharmacol 138:413-416
25. Molewijk HE, van der Poel AM, Mos J, van der Heyden JAM, Olivier B (1995) Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening antipanic drugs. Psychopharmacology 117:32-40
26. Nixon MK, Hascoet M, Bourin M, Colombel MC (1994) Additive effects of lithium and antidepressants in the forced swimming test : further evidence for involvement of the serotonergic system. Psychopharmacology 115:59-64
27. Olivier B (1992) Animal models in obsessive compulsive disorder. Int Clin Psychopharm 7[1]:27-29
28. Olivier B, Mos J (1992) Rodent models of aggressive behavior and serotonergic drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 16:847-870
29. Olivier B, Bosch L, van Hest A, van der Heyden J, Mos J, van der Poel G, Schipper J, Tulp M (1993) Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry 26:2-9
30. 2 binding site, Part 1. 3-(ω-amínoalky1)-1H-indoles. J Med Chem 38:1998-2008
31. 3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 206:243-250
32. Porsolt RD, Bertin A, Jalfre M (1977) behavioural despair in mice; a primary screening test for antidepressants. Arch Int Pharmacodyn 229:327-336
33. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57:201-210
34. Rao TS, Cler JA, Mick SJ, Ragan DM, Lanthorn TH, Contreras, PC, Iyengar S, Wood PL (1990) Neurochemical characterization of dopaminergic effects of opipramol. a potent sigma receptor ligand, in vivo. Neuropharmacology 29:1191-1197
35. Sánchez C (1993) Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav Pharmacol 4: 269-277
36. Sánchez (1995) Serotonergic mechanisms involved in the exploratory behavior of mice in a fully automated two-compartment black and white test box. Pharmacol Toxicol 77:71-78
37. 1A receptors play an important role in mediation of exploratory behavior of rats in a two-compartment black and white box. Behav Pharmacol (in press)
38. 1A receptors. Eur J Pharmacol 264:241-247
39. Sánchez C, Arnt J, Hyttel J, Moltzen EK (1993) The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology 110:53-59
40. Sánchez C, Arnt J and Perregaard J (1994) Lu 28-179 -a selective sigma ligand with potent anxiolytic effects. Soc Neurosci Abstr 20:164,16
41. 3H]3-PPP binding to σ sites in rat brain. Eur J Pharmacol 165:335-336
42. Sheehan DV, Raj BA, Trehan RR, Knapp EL (1993) Serotonin in panic disorder and social phobia, Int Clin Psychopharmacol 8[2]:63-77
43. Shirayama Y, Nishikawa T, Umino A, Takahashi K (1993) p-Chlorophenylalanine-reversible reduction of σ binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol 37:117-126
44. 3H]toly1)guanidine: a selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83:8784-8788